Acarix
AI-powered acoustic system for rapid, non-invasive rule-out of Coronary Artery Disease.
ACARIX | ST
Overview
Corporate Details
- ISIN(s):
- SE0009268717 (+1 more)
- LEI:
- 549300KP2XS4513DEI67
- Country:
- Sweden
- Address:
- HYLLIE BOULEVARD 34 5 TR, 215 32 MALMÖ
- Website:
- https://www.acarix.com/
- Sector:
- Manufacturing
Description
Acarix is a medical technology company dedicated to transforming early cardiac diagnostics. Its primary product, the CADScor® System, is an AI-powered diagnostic aid that enables healthcare professionals to non-invasively rule out significant Coronary Artery Disease (CAD) at the point of care. The system uses highly sensitive acoustic technology and advanced computational processing to analyze coronary blood flow, providing a rapid, radiation-free risk stratification. This allows for immediate clinical decisions, potentially reducing the need for costly and invasive secondary evaluations in settings like emergency rooms and outpatient clinics. The CADScor® System is supported by extensive clinical data and has received both CE-marking and FDA De Novo clearance.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Acarix filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Acarix
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Acarix via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Aamir Mahmood | Other | Buy | 1,382,000 | 317,860.00 SEK |
| 2025-02-13 | Aamir Mahmood | Other | Buy | 918,257 | 192,833.97 SEK |
Peer Companies
